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b-Amyloid (Ab) accumulation is an early event of Alzheimer’s disease (AD) pathogenesis. Inhibition of Ab
production by b-secretase (BACE) has been proposed as a potential therapeutic strategy for AD. However,
BACE inhibitors lack speciﬁcity and have had limited clinical beneﬁt. To better study the consequences of
reducing BACE metabolism, speciﬁcally of APP, we used an antibody, 2B3, that binds to APP at the BACE
cleavage site, inhibiting Ab production. 2B3 was administered either directly into the lateral ventricles or
by intraperitoneal injection to (platelet-derived growth factor promoter hAPP717V (PDAPP) mice and WT
mice. 2B3 reduced soluble Ab40 and bCTF (b-amyloid derived C-terminal fragment) and improved
memory for object-in-place associations and working memory in a foraging task in PDAPP mice. 2B3 also
normalized the phosphorylation of the N-methyl-D-aspartate receptor NR2B subunit and subsequent
extracellular signaleregulated kinase signaling. The importance of this NR2B pathway for OiP memory
was conﬁrmed by administering the NR2B antagonist, Ro25-6981, to 18-month-old WT. In contrast, 2B3
impaired associative recognition memory in young WT mice. These data provide novel insights into the
mechanism by which selective modulation of APP metabolism by BACE inﬂuences synaptic and cognitive
processes in both normal mice and aged APP transgenic mice.
 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The excess accumulation of b-amyloid (Ab) in the brainwith age
is considered an important factor in the cascade of cellular, neural
network, and cognitive changes that characterize the early stages of
Alzheimer’s disease (AD) (Hardy and Selkoe, 2002; Selkoe, 2001).
Ab is produced by the proteolytic cleavage of amyloid precursor
protein (APP) by the b-secretase cleavage enzyme (BACE1). BACE1 is
located in the presynaptic terminals of neurons and is thought to be
critical for the production of Ab and subsequent disruption of
synaptic connectivity that characterizes early-stage AD (Sadleir
et al., 2016).
One approach to altering APP metabolism is through the use of
BACE1 inhibitors (Yan andVassar, 2014). However, this approach has
beenproblematic because BACE1 hasmultiple substrates other than
APP (Hemming et al., 2009). Although BACE1 modulation in peopleardiff University Park Place,
þ44 2920 874858.
k (M.A. Good).
er Inc. This is an open access articwith clinically diagnosed dementia appears to lack therapeutic ef-
ﬁcacy, the targeting of this pathway in the elderly with cognitive
decline or those at high risk of dementia remains an area of current
interest. Therefore, understanding the effects of selectively modi-
fying BACE1-APP processing on synaptic function and cognition is
vital to understanding the mechanism and the conditions under
which such an intervention may have therapeutic value.
In the present study, we used a monoclonal antibody, 2B3,
directed against the BACE1 cleavage site of APP to reduce BACE1
cleavagewithout inﬂuencing other BACE1 substrates (Thomas et al.,
2013, 2011b). We hypothesized that in vivo administration of 2B3
either directly into the brain or systemically into an aged mouse
model of excess Ab accumulation would (1) reduce Ab production,
(2) improve aberrant synaptic processes in the hippocampus, and
(3) improve visuospatial associative recognition memory. In
experiment 1, we ﬁrst established the age of onset of a selective
associative (object-in-place [OiP]) recognition memory deﬁcit in
transgenic platelet-derived growth factor promoter hAPP717V
(PDAPP)mice; a task that relies on a brain network that includes the
hippocampus (Barker and Warburton, 2011). In experiment 2a, wele under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cerebroventricular (ICV) administration of the antibody, 2B3, on
associative memory dysfunction in aged PDAPP mice. In experi-
ment 2b, we addressed the question of whether disruption of
endogenous APP processing by 2B3 in normal mice inﬂuenced
associative recognition memory. In experiment 3, we investigated
the effects of chronic intraperitoneal (IP) administration of 2B3,
initiated before the onset of behavioral impairment, on the subse-
quent development of cognitive dysfunction in aged PDAPP mice.
Finally, experiment 4 used a within-subject Latin-square design to
test the hypothesis that disruption of glutamate signaling through
N-methyl-D-aspartate (NMDA) NR2B receptors, evident in PDAPP
mice from experiments 2 and 3, was required for normal associative
recognition memory inWTmice. Our results show for the ﬁrst time
that selective reduction in APP metabolism by BACE1 using steric
hindrance both improved and protected mice from memory
dysfunction and altered synaptic NMDA-NR2B expression in PDAPP
mice.
2. Materials and methods
2.1. Animals
Male PDAPP mice (Games et al., 1995), and their WT littermates,
were bred and maintained on a C57Bl/6 genetic background as
previously described (Evans et al., 2018). Mice were housed either
individually (if they showed signs of aggressive behavior) or in
groups. OneWTand one transgenic mouse were housed separately.
All animals were housed using standard environmental and cage
conditions, including nesting cardboard tubes and clean bedding.
Behavioral testingwas carried out during the light hours of the cycle.
Animals were maintained according to the UK Home Ofﬁce under
the Animal Scientiﬁc Procedures Act (1986) and EU regulations.
Before assignment to groups, the mice were genotyped ac-
cording to protocols described previously (Evans et al., 2018).
Brieﬂy, an ear biopsy sample was collected from each mouse at 6-
8 weeks of age as part of animal husbandry identiﬁcation proced-
ures, which was then digested and DNA extracted using DNeasy
Blood and Tissue kits (Qiagen). A polymerase chain reaction was
used to amplify the human APP V717F transgene DNA. PDAPP-
speciﬁc primers forward: 5’-ATCTGGCCCTGGGGAAAAAAG-3’ and
reverse: 5’-GATGTCCTTCCTCCTCTGTTC-3’ (Euroﬁns, Wolverhamp-
ton, UK) ampliﬁed the hAPP V717F mutation. Control primers for
MusA-Actin forward: 5’-CACCACACCTTCTACAATGAGCTG-3’ and
reverse: 5’-TCATCAGGTAGTCAGTGAGGTCGC-3’ (Euroﬁns) targeted
MusA-Actin.
Experiment 1 established the age of onset of cognitive impair-
ment, andexperiment 2 assessed the effects of ICV infusionof 2B3on
cognition in the same animals. ICV administration was considered
themost appropriatemeans to ensure the delivery of the antibody in
the brain and thus provide a test of its putative actions in vivo as
evidenced from our previous cell culture experiments. Experiments
1 and 2a consisted of 2 replications: The ﬁrst replication comprised
PDAPP (n ¼ 14) and WT littermates (n ¼ 15), which underwent a
battery of object memory tests at 6-8, 10-12, and 14-16 months of
age. Subsequently, these mice received ICV 2B3 (Thomas et al.,
2011b, 2013) or vehicle at 17-18 months of age using osmotic min-
ipumps (experiment 2a). A second replication of 17- to 18-month-
oldWT (n¼8) andPDAPP (n¼8)mice received the sameschedule of
prior training (age-of-onset testing; data not shown) and 2B3
administration. Together, these subgroups yielded a ﬁnal total
numberof 11WTuntreated,10WTvehicle,11 vehicle PDAPPvehicle,
and 10 2B3 PDAPP mice (1 WT and 1 PDAPP mouse died during
osmotic minipump implantation). A separate third cohort of PDAPP
micewas usedonly to conﬁrmandquantify aging-related changes inhuman Ab levels at 3 (n ¼ 5), 7 (n ¼ 7), 11 (n ¼ 7), and 15 (n ¼ 7)
months of age; these mice did not undergo behavioral testing. For
experiment 2b, a separate cohort of 5- to 6-month-old WT mice
were administered either 2B3 or a control mousemonoclonal IgG1k
antibody (Millipore; MAB201) by osmotic minipump to investigate
the effects on cognition of disrupting endogenous mouse APP pro-
cessing with 2B3. Experiment 2b consisted of 8 WT mice that
received the control IgG antibody and 8 mice that received ICV 2B3
via osmotic minipumps. As 1mouse died postoperatively before the
start of behavioral testing, it was removed from subsequent ana-
lyses. The ﬁnal n’s were, therefore, 8 WT control and 7 WT 2B3.
In experiment 3, PDAPP (n ¼ 19) and WT littermate controls
(n ¼ 20) were used to assess the protective effects of long-term
administration of 2B3 that was initiated before the onset of
cognitive impairment. As long-term administrationwas not feasible
using an ICV minipump delivery method, 2B3 was administered to
PDAPP mice (n ¼ 9) by once weekly IP injection at 20 mg/kg for a
period of 15 weeks from 11 months of age. Vehicle was adminis-
tered at an equal volume in control WT (n ¼ 10) and PDAPP mice
(n ¼ 10). An additional WT untreated group (n ¼ 10) was included
to assess the potential impact of IP treatment on performance. The
initial behavioral tests were carried out at 11 months of age, before
2B3 administration. All treatment groups were then subsequently
matched in terms of their object contact times and discrimination
ratios (data not shown). After a further 15 weeks of IP injections,
memory function was tested at 15 months of age. These mice were
tested on object memory tasks and a spatial working memory
foraging task (Evans et al., 2018) to establish the generality of the
behavioral effects of 2B3 administration across different perfor-
mance measures. A breakdown of the experimental designs is
illustrated in Figure 1.
Experiment 4 evaluated the hypothesis that NMDA-NR2B re-
ceptor function was necessary for associative recognition memory
inWTmice. A naïve cohort of 18-month-oldWT littermate controls
(n¼ 10) was administered the NR2B receptor antagonist Ro25-6981
or vehicle 30 minutes before behavioral testing. The experiment
was run as a within-subject Latin-square design. A Latin-square is a
commonly used experimental design to assess the effects of drug(s)
and vehicle in the same animals on performance in a counter-
balanced fashion.
Mice were given a 48-hour rest interval between each injection
as a washout period before the next phase of testing. Novel objects
were used in each phase of drug testing, and their order was
counterbalanced across animals.
2.2. Behavior
In experiments 1 and 2, mice received 2 different object-based
memory tasks; a novel object recognition task and a visuospatial
OiP task (Barker and Warburton, 2011; Good and Hale, 2007; Hale
and Good, 2005) (Fig. 2A and B). Brieﬂy, before testing object
memory, animals were habituated to the arena (60 cm  60 cm
square 40 cm high). Micewere allowed to explore the arena freely
for 10 minutes on day 1. Mice were then habituated for 2 consec-
utive days to the arena containing 2 identical objects for 10 minutes
each day. Each mouse received 2 rounds of testing on each task, 1
day with a 5-minute and 1 day with a 24-hour delay period (in a
counterbalanced order). The objects were a collection of every day
items and ornaments as described previously (Hale & Good, 2005).
2.2.1. Novel object recognition
To assess object novelty versus familiarity discriminations, 2
identical objects were placed in the center of the arena and mice
were allowed to explore the objects for 10 minutes during the
sample phase. Mice were given a total of 3 sample phases, each
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Figure 1. Schematic illustration detailing experimental designs used in this study. (A) Experiment 1 assessed cognitive performance (object-novelty and OiP performance) of PDAPP and
WT littermate controls at 3 age points across the study. Experiment 2a used the same mice to assess whether 2B3 (icv) infusion by osmotic minipumps could improve OiP memory and
pathology in PDAPP mice. (B) A separate cohort of PDAPPmice was used to exclusively determine the age-related changes of b-amyloid pathology in the hippocampus of PDAPP mice using
time points comparable to the behavioral time points used in seperate experiments. (C) A separate cohort of WT mice was administered 2B3 to assess its effect on normal endogenous
mouse APP processing and memory. These mice ﬁrst received behavioral testing (object-novelty and OiP memory) prior to implantation of osmotic minipumps. Subsequently, they were
administered 2B3 or IgG control antibody for 14 days. Memory function was then reassessed before culling and assessment of endogenous APP metabolism. (D) The effects of 2B3
administered longitudinally via a peripheral (i.p.) route on cognition was assessed in a separate cohort of PDAPP mice. These mice ﬁrst received pretreatment behavioural testing (object
novelty, OiP, and foraging behavior tasks) at 11 months of age. After which, the mice were administered 2B3 or vehicle i.p. for 15 weeks. During treatment weeks 13-15, memory function
was reassessed, following which, the mice were culled and brain pathology was analysed. (E) Experiment 4 assessed the role of the NR2B receptor in OiP memory in normal WT mice. This
was carried out in a Latin-square designwhereby the cohort was split into 2 groups (A and B; each group n¼ 5). Group Awere initially assessed on the task after Ro25-6981 administration,
while group B after vehicle treatment. After this initial assessment, Ro25-6981 was then administered to group Bmice, while group Amice now received vehicle. Abbreviations: OiP, object-
in-place; WT, wild type.
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Figure 2. Schematic diagram illustrating object novelty and object-in-place recognition memory tasks. To assess novel object memory (A) mice were presented with 2 identical
objects for 3 separate 10-minute sample phases, each separated by a 5-minute delay during which the mouse was returned to its home cage. Five minutes or 24 hours later, novel
object memory was tested by presenting the mouse with 1 familiar object and one novel object and recording the contact time with each. Object-in-place memory (B) was tested in
a similar fashion except 4 unique objects were used. In the test phase, 2 objects were switched spatial location and 2 remained in the same familiar locations. The contact times with
objects in novel and familiar locations were recorded.
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mouse was returned to its home cage. Following the third sample
phase, mice received either a 5-minute or 24 hour delay period, the
order of which was counterbalanced within groups. During the test
phase, 1 familiar and 1 novel object were then placed into the arena
in identical spatial locations as the sample objects (Fig. 2A). The
mouse was then returned to the arena for 10 minutes to explore the
object array.
2.2.2. Associative OiP memory
Four different objects were placed in the center of the arena in a
square formation. Each object was approximately 15 cm from the
walls and 25 cm apart from each other. Mice were placed in the
center of the arena and exposed to the 4 different objects for 3
sample phases and a test phase as described for the object novelty
test. In the test phase, conducted 5 minutes after the sample phase,
the spatial location of 2 objects that were positioned diagonally
opposite each other was switched (Fig. 2B). The speciﬁc pair of
objects that underwent the switch was counterbalanced within and
between groups.
2.2.3. Behavioural measures
For both recognition tasks, the animals’ exploratory behavior
was assessed during both the sample and test phases. Time spent
exploring the objects was recorded in each phase. Object explora-
tion was deﬁned according to the methods described previously by
Ennaceur and Delacour (1988). In brief, object contact was deﬁned
as when an animal was within a 2 cm radius of the object and
directly facing, snifﬁng, gnawing, but not climbing or sitting on, the
objects. A discrimination ratio (DR) was used to index the animals’
discriminative performance in the test phase that was independent
of individual differences in object contact times; this was calculated
as the time spent exploring the novel object (or objects in novel
locations)/the time spent exploring all objects. All objects were
cleaned before each phase of testing to reduce the use of odor cues
introduced from handling the objects.
2.2.4. Foraging behavior
To establish the generality of the cognitive changes promoted by
2B3 administration, mice that received longitudinal IP 2B3 in-
jections were also assessed on a foraging-based spatial working
memory task sensitive to age-dependent changes in PDAPP mice
(Evans et al., 2018). Brieﬂy, throughout the training and test phase,
mice were water-deprived to approximately 90% of their pre-
training weight. Water was given for 4 hours immediately after
training or testing each day. Mice were trained to forage fromwhite
ceramic pots (6.5 cm diameter, 3.5 cm depth; Lakeland, UK), which
were mounted on a wooden cube base. Pots were secured to theﬂoor of the cage/arena with blue-tack. In the initial training stages
(day 1-3), pots containing 10 mL of water were placed in the home
cage of mice for 1 hour to encourage mice to consume liquid re-
wards from within the pot. The following 3 days (day 4-6), 2 pots
were baited with a 30 mL liquid reward (1:3 sweetened condensed
milk [Nestle] solution, prepared in water; H20) in an open arena
with 1-cm-deep sawdust covering the arena ﬂoor. Mice were
placed in the center of the arena and given 3minutes to forage from
each pot. Micewere removed once the liquid rewardwas consumed
from each pot or the 3-minute limit was reached. Mice were given 1
training session/day. On each day, the location of the pots was
moved to a new location to prevent the development of any sys-
tematic search bias in the test phase.
Mice were then tested over the next 4 consecutive days with 1
session per day. During these sessions, the arena was set up with 6
pots arranged in a circular pattern, each 20 cm apart. The mouse
was placed in the center of the arena and allowed to forage pots
until they had consumed all 6 rewards or until a 10-minute period
had elapsed from when the ﬁrst pot was foraged. Following the
trial, mice were returned to their home cage. The pots were then
wiped clean with 70% ethanol wipes, and the milk solution
replenished before the next mouse was tested. All test sessions
were recorded onto a DVD player using an overhead camera.
Foraging behavior was deﬁned as a mouse jumping onto the rim
of a pot and directing its nose in toward the bottom to consume a
reward. An error was deﬁned as amouse returning to forage in a pot
that had previously been foraged. A full description of errors can be
found in Evans (2018).2.3. Antibody production and administration
Full details of the immunization protocol, hybridoma develop-
ment, antibody characterization, production, and puriﬁcation are
provided elsewhere (Thomas et al., 2006, 2011b, 2013).
In Experiments 2a and 2b, puriﬁed and sterilized 2B3 (1.2 mg/
mL), control monoclonal IgG1k antibody (experiment 2b) and
vehicle (experiment 2a) were administered intra-
cerebroventricularly via a 28G cannula surgically implanted into
the left lateral ventricle (Alzet; 0004760). The minipumps were
attached to the infusion cannula via a catheter and implanted
subcutaneously between the scapulae. Minipumps were ﬁlled with
200 mL of antibody or vehicle (Model number 1002; Alzet, Califor-
nia, USA; ﬂow rate 0.25 mL/hour for a period of 14 days). In exper-
iment 2a, the vehicle was sterile PBS and was administered to both
PDAPP mice (n ¼ 11) and WT littermate control groups (n ¼ 10). In
experiment 2b, the WT control group received ICV infusion of a
monoclonal IgG1k.
Table 1
Primary antibodies used in Western blotting
Primary antibody Species Dilution Source
APP (22C11) Mouse 1:1000 Millipore
BACE1 Rabbit 1:1000 Cell Signalling Technology
NMDA-NR1 Mouse 1:1000 BD Biosciences
NMDA-NR2B Rabbit 1:500 Millipore
NMDA-NR2B
pY1472
Rabbit 1:750 Millipore
PSD95 Rabbit 1:1000 Abcam
PS1 Rabbit 1:500 Santa Cruz
Fyn Mouse 1:750 BD Biosciences
STEP Mouse 1:750 Novus
ERK Rabbit 1:2000 Cell Signalling Technology
Phospho-ERK Rabbit 1:1000 Cell Signalling Technology
GAPDH Pre-conjugated 1:50,000 Sigma
b-Actin Pre-conjugated 1:20,000 Sigma
Key: ERK, extracellular signaleregulated kinase; NMDA, N-methyl-D-aspartate;
STEP, striatal-enriched phosphatase.
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15 weeks. 2B3 was produced by ascites (ProMab, California, USA),
before being puriﬁed and sterilized as described previously. PDAPP
micewere administered 2B3 (IP) at a dose of 20mg/kg at an average
concentration of 3mg/mL. Sterile PBSwas administered at the same
volume to vehicle PDAPP and WT mice control groups. After the
completion of behavioral testing and 3 days after the ﬁnal IP in-
jection of 2B3, brain tissue was collected from all mice for
biochemical analyses.
2.4. Surgical procedure
During stereotaxic surgery, the mouse was anesthetized using
an isoﬂurane/O2 mix, and a small hole was drilled through the skull
of the animal 0.5 mmposterior and 1.2mm lateral to Bregma. A 28G
cannula was then inserted 3.0 mm ventral to the skull surface and
ﬁxed in place by dental acrylic. The minipump was carefully
inserted into a subcutaneous pocket between the scapulae, the skin
incision sutured, and the mouse allowed to recover in an incubator
until independently mobile. Following standard postoperative care
procedures, the mice were then housed individually for the dura-
tion of the study.
Postoperative behavioral testing on the OiP associative recog-
nition task occurred 9 days after surgery and used the procedure
described in experiments 1 and 2. On day 14, following behavioral
testing, the animals were culled and brain tissue collected for
analyses.
2.5. Ro25-6981 administration
Ro25-6981 (Tocris, Abingdon, UK) was dissolved in sterile saline
at a ﬁnal concentration of 5 mg/mL. Mice were administered a
single 10 mg/kg dose of Ro25-6981 or vehicle IP, 30 minutes before
the start of the associative recognition OiP task. This dose was
selected based on previously published behavioral work (e.g.,
Mikics et al., 2017).
2.6. Pathology: protein extraction and immunoblots
The hippocampus and cortex were dissected, snap-frozen in
liquid nitrogen, and stored at 80 C. Soluble proteins were
extracted from brain samples as previously described (Thomas
et al., 2011a). For the ICV study, all blots quantifying changes in
soluble protein levels for the ICV study assessed 10 WT vehicle, 11
PDAPP vehicle, and 10 PDAPP mice administered 2B3 intra-
cerebroventricularly. For the IP study analysis, 9 WT vehicle, 10
PDAPP vehicle, and 9 PDAPP 2B3-administered mice were assessed.
Synaptosome extractions were performed using Syn-PER synaptic
protein extraction reagent (Thermo Fisher, UK). Western blotting
was performed using standard methods as described previously
(Thomas et al., 2011a) using samples from all animals undergoing
treatment and behavioral testing. Brieﬂy, after protein quantiﬁca-
tion, 20 mg of protein/sample was resolved on either a 10% or 7.5%
polyacrylamide gel and detected with the relevant antibody
(Table 1). The right hippocampus of all 10 WT vehicle, 11 PDAPP
vehicle, and 10 PDAPP mice administered 2B3 intra-
cerebroventricularly were used to assess synaptic protein changes.
2.7. Sandwich ELISA for detection of APP metabolites
ELISAs for the quantiﬁcation of Abwere carried out as previously
described (Thomas et al., 2011a,b), or as recommended by the
manufacturer: APP (R&D Systems, Abingdon, UK), b-amyloid
derived C-terminal fragment (bCTF; IBL, Hamburg, Germany), and
Ab40 and Ab42 (human and mouse; Invitrogen, California, USA).Data are presented as ng or pg/mg total protein concentration.With
exception of experiment 2b, which assessed endogenous mouse
Ab40 and Ab42, all further ELISAs were sensitive to human protein
only. Therefore, the PDAPP mice that expressed the human
APPV717F were used. The ICV study used 11 PDAPP vehicle mice
and 10 PDAPP 2B3 mice (however, 1 mouse was removed as an
outlier as explained below). The IP study used 10 PDAPP vehicle
mice and 9 PDAPP 2B3 mice to quantify protein levels by ELISA.
2.8. Statistical analyses
All statistical analyses were performed using IBM SPSS statistics.
The behavioral data conformed to the assumptions of analysis of
variance (ANOVA) and were analyzed using a mixed measures
design. Signiﬁcant interactions were assessed using tests for simple
main effects. Western blot data were analyzed using one-way
ANOVA followed by Tukey’s post hoc analysis. WT data were
collapsed across treatment (untreated and vehicle) for the analysis
of the cognitive and behavioral effects of 2B3 administration as no
group differences were observed between WT groups p’s > 0.5
(data not shown). ELISA data were analyzed using either Student’s
t-test or a Kruskal-Wallis test with Dunn’s test along with a Bon-
ferroni correction for multiple comparisons. All datawere subject to
Levene’s and Shapiro-Wilks’ tests for data normality before anal-
ysis. Appropriate transformations were carried out when necessary.
Data generated from ELISA assays were quantiﬁed by comparing
data to standard curves from each plate using GraphPad Prism 4
and normalized to total protein concentration. One PDAPP 2B3-
treated mouse was found to be an extreme outlier across the
ELISA analyses of the 2B3 ex vivo tissue, as determined by SPSS
Tukey box plots and more conservative methods for labeling out-
liers, as described previously (Carling, 1998; Hoaglin and Iglewicz,
1987). No transformation was able to normalize this outlier for
either parametric or nonparametric analysis. Therefore, the data
from this 1 mouse were removed from all ELISA analyses but no
other analysis. The result of this exclusion was that all remaining
ELISA data sets were normally distributed, and its exclusion did not
change the pattern of results. Western blots were quantiﬁed using
Image J software (www.imagej.nih.gov/).
3. Results
Experiment 1 used object novelty and OiP tasks to determine the
nature and age of onset of memory deﬁcits in PDAPP mice. In the
second stage of the study, experiment 2a, the same animals were
administered the APP antibody 2B3, at 17-18 months of age, via
osmotic minipumps for a period of 14 days. Having established that
C.E. Evans et al. / Neurobiology of Aging 75 (2019) 136e149 1412B3 reversed pre-existing associative recognition memory impair-
ment, experiment 3 determined whether longitudinal peripheral
administration of 2B3 prevented the onset of cognitive decline in
PDAPP mice.3.1. Experiment 1
During development, WT mice showed a greater overall object
contact time during sample phases across both tasks and at all ages,
than PDAPP mice, p’s < 0.01 (Supplementary Table 1). However,
analysis showed that both WT and PDAPP mice habituated nor-
mally across the 3 sample phases, as indicated by a decline in object
contact times (Supplementary Table 1). In the test phase, WT mice
showed a greater contact time with objects than PDAPP mice, p <
0.001 across all ages (Supplementary Table 2). However, both WT
and PDAPP mice showed a preference to explore objects in novel
locations more than familiar locations both at 6-8 and 10-
12 months of age, p values <0.01. However, at 14-16 months of age,
only WT but not PDAPP mice showed this preference, (p < 0.001
and p> 0.05, respectively; data collapsed across both delays). There
were no signiﬁcant interactions involving genotype and delay for
either task (see Supplementary Analysis). In contrast, both WT and
PDAPP mice showed a preference to explore novel objects across all
ages and delays, p values <0.01, and showed no genotype differ-
ence, even at 14-16 months of age (p > 0.05; Supplementary
Table 2).
An analysis of DRs similarly showed an identical pattern with
PDAPPmice performance, as well asWTmice, on the novelty test at
all ages as indicated by no main effect of genotype, F(1, 27) ¼ 2.5, p
> 0.1, and no genotype  age interaction, F(1, 27) ¼ 2.8, p > 0.1. In0.4
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Figure 3. PDAPP mice show an age-dependent decline in OiP memory performance and an i
memory across any age or delay compared to WT littermates (n ¼ 15). (B) However, a signiﬁ
impairment in OiP memory at 14-16 months of age across both delays compared to WT litter
16 months of age compared to their performance at 6-8 and 10-12 months of age. DR scor
signiﬁcant interactions. (C-D) Levels of soluble Ab40 and Ab42 were then assessed in a sepa
age. (C) Levels of soluble Ab40 and (D) Ab42 increased with age in the hippocampus of PDAPP
Wallis test with Dunn’s post hoc analysis with Bonferroni corrections. *p < 0.05; ***p < 0.0
analysis of variance; DR, discrimination ratio; OiP, object-in-place; WT, wild type.contrast, PDAPPmice were signiﬁcantly impaired relative to control
mice only at 14-16 months of age for the OiP task (see Fig. 3A and
3B). Analysis of the OiP task revealed a signiﬁcant age  genotype
interaction, F(2, 54)¼ 9.2, p< 0.05. Subsequent tests of simplemain
effects revealed that PDAPP mice showed a signiﬁcant main effect
of age with a reduction in OiP memory performance across age
ranges, F(2, 26) ¼ 9.8, p < 0.001. Further analysis revealed that
PDAPP mice showed a signiﬁcant memory deﬁcit compared with
WT mice only at 14-16 months of age, F(1, 27) ¼ 49.9, p < 0.001.
There was no signiﬁcant interaction involving delay, F < 1. The
analysis of DR values conﬁrmed that PDAPP mice showed an age-
dependent deﬁcit in associative recognition memory, without
affecting object novelty/familiarity discriminations.
An analysis of age-related changes in hippocampal Ab levels in a
separate group of PDAPP mice conﬁrmed a numerical 3.6-fold in-
crease in soluble Ab40 levels (Fig. 3C; nonsigniﬁcant following
analysis by the Kruskal-Wallis test, X2(3) ¼ 2.7, p > 0.1) and a sig-
niﬁcant, X2(3) ¼ 10.5, p < 0.05, 32-fold increase in soluble Ab42
levels by 15 months of age (Fig. 3D). Dunn’s test for multiple
comparisons showed a signiﬁcant increase in the levels of soluble
Ab42 when comparing mice at 3 months and 15 months of age, p <
0.05. Thus, PDAPP mice showed an age-related increase in amyloid
pathology with a marked increase in Ab production at the same age
as behavioral deﬁcits emerged in a separate cohort of mice.3.2. Experiment 2
3.2.1. Experiment 2a
After 2B3 or vehicle administration, PDAPP mice continued to
explore all 4 objects less thanWTmice, p values<0.01. However, all0.4
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ncrease in amyloid levels. (A) PDAPP mice (n ¼ 14) showed no deﬁcits in object novelty
cant age vs genotype interaction revealed that PDAPP mice showed an age-dependent
mates. There was also a signiﬁcant decline in the OiP performance of PDAPP mice at 14-
es were analyzed using 3-way ANOVA with Bonferroni corrected post hoc analysis for
rate colony of mice at 3 months (n ¼ 5), 7 (n ¼ 7), 11 (n ¼ 7), and 15 months (n ¼ 7) of
mice. Ab levels were quantiﬁed by ELISA assays. Data were analyzed using the Kruskal-
01. Error bars represent the standard error of the mean (SEM). Abbreviations: ANOVA,
C.E. Evans et al. / Neurobiology of Aging 75 (2019) 136e149142mice continued to show reduced contact times across sample trials,
p’s< 0.001 (Supplementary Table 3A). During the test phase, overall
mice showed a preference to explore objects in novel locations over
familiar, p < 0.001 (Supplementary Table 4A). However, WT mice
had higher contact times with objects both in familiar and novel
locations than vehicle PDAPP mice, p values <0.01, and PDAPP 2B3-
treated mice, p values <0.05. No signiﬁcant differences in contact
times were observed between PDAPP treatment groups, p > 0.1.
An analysis of the DRs, however, showed a signiﬁcant
treatment  time point interaction, F(2, 39) ¼ 3.27, p < 0.05. Tests
of simple main effects revealed that PDAPP mice administered ICV
2B3 showed a signiﬁcant improvement in performance compared
to both their pre-administration, p < 0.01, and to vehicle PDAPP
mice performance, p < 0.001. In contrast, vehicle PDAPP mice
remained signiﬁcantly impaired relative to WT controls, p < 0.001,
and 2B3 PDAPP mice were not signiﬁcantly different to WT mice, p0.4
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Figure 4. 2B3 administration prevents the onset of and reverses age-dependent cognitive d
showed a signiﬁcant improvement in OiP memory compared with their pretreatment score
(n ¼ 11; ***p < 0.001). No difference in DR scores were reported when comparing WT mice
remained impaired compared with WT mice (###p < 0.001). (B) Peripheral administration o
no decline in OiP performance occurred after 15-week 2B3 administration, p > 0.05. 2B3 PD
(***p < 0.001), which did show an age-dependent decline in OiP performance (AAp < 0.01)
vehicle n ¼ 10; ###p < 0.001), whereas 2B3-administered PDAPP mice were not. (C) No si
when comparing novel object recognition memory, indicating all mice were able to encode o
foraging errors compared with WT mice (###p < 0.001). PDAPP mice administered 2B3, how
than their pre-2B3 administration scores (Ap < 0.05). (E) Peripheral vehicle PDAPP mice sho
which was not observed following 2B3 administration (p > 0.05). Vehicle PDAPP mice mad
controls (##p < 0.01). DR scores and foraging errors were analyzed using a 3-way ANOVAwi
the SEM. Abbreviations: ANOVA, analysis of variance; DR, discrimination ratio; ICV, intracer> 0.5 (see Fig. 4A). Thus, ICV infusion of 2B3 in PDAPP mice
reversed an age-dependent deﬁcit in associative recognition
memory.
3.2.2. Experiment 2b
To investigate further how inhibition of APP metabolism at the
BACE1 cleavage site affected healthy WT control animals, a sepa-
rate group of mice were directly administered ICV 2B3. Similar to
PDAPP mice, 2B3 administration in WT mice showed no overall
changes in object contact times across sample phases for object
novelty and OiP tasks relative to WT IgG1k controls, p’s > 0.1 nor
during the test phases, p’s > 0.1 (Supplementary Table 3C and 4C,
respectively). Interestingly, while both 2B3 and control WT IgG1k
mice explored novel objects in preference to familiar objects, a
numerical reduction in contact times with objects in novel loca-
tions was observed in 2B3 mice (Supplementary Table 4C);0.4
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eﬁcits in PDAPP mice. (A) PDAPP mice treated with 2B3 (n ¼ 10) by ICV administration
s (AAp < 0.01) and performed signiﬁcantly better than vehicle-treated PDAPP mice
(untreated n ¼ 11, vehicle n ¼ 10) to PDAPP 2B3 mice. However, vehicle PDAPP mice
f 2B3 to PDAPP mice (n ¼ 9) before the onset of impaired OiP performance showed that
APP mice further showed a greater OiP performance than vehicle PDAPP mice (n ¼ 10),
. PDAPP vehicle mice were further impaired compared with WT mice (untreated n¼ 10,
gniﬁcant differences were reported between groups in peripheral 2B3 administration
bject information. (D) Peripheral PDAPP vehicle mice showed an age-related increase in
ever, made less foraging errors than PDAPP vehicle controls (**p < 0.01) and less errors
wed an age-dependent increase in repeat errors made in the foraging task (Ap < 0.05),
e signiﬁcantly more repeat errors than 2B3 PDAPP mice (*p < 0.05) and WT littermate
th Bonferroni corrected post hoc analysis for signiﬁcant interactions. Error bars express
ebroventricular; OiP, object-in-place; SEM, standard error of the mean; WT, wild type.
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Figure 5. 2B3 inhibits APP metabolism by BACE and reduces Ab production. (A) 2B3 administration by ICV in PDAPP mice (n ¼ 10) showed no overall changes in total levels of
BACE1 or PS1 in the hippocampus compared with PDAPP vehicle mice (n ¼ 11) or WT vehicle mice (n ¼ 10), p’s > 0.5, as determined byWestern blot. However, ICV vehicle and 2B3
PDAPP mice showed a signiﬁcant increase in total levels of APP (***p < 0.001,AAAp < 0.001), respectively, relative to WT littermates as determined by one-way ANOVAwith post
hoc Tukey analysis. (B) Similar to ICV mice, after IP administration of 2B3 to PDAPP mice (n ¼ 9), no change in BACE1 or PS1 was observed compared with vehicle PDAPP (n ¼ 10) or
WT mice (n ¼ 9). (C and D) When protein levels were quantiﬁed using ELISA, PDAPP mice administered with 2B3 showed no change in total levels of APP after ICV (n ¼ 9) or IP (n ¼
9) administration of 2B3 compared with vehicle PDAPP mice (ICV n ¼ 11, IP n ¼ 10). (E) ICV 2B3 administration caused a signiﬁcant reduction in bCTF, and (F) soluble Ab40 and (G) a
nonsigniﬁcant reduction in soluble Ab42 in the hippocampus of PDAPP mice. (H-K) No signiﬁcant changes in amyloid levels were observed in IP 2B3-administered mice compared
with vehicle PDAPP mice. Data were analyzed using independent samples t-tests. *p < 0.05. Error bars express the SEM. Abbreviations: ANOVA, analysis of variance; DR,
discrimination ratio; ICV, intracerebroventricular; IP, intraperitoneal; OiP, object-in-place; SEM, standard error of the mean; WT, wild type.
C.E. Evans et al. / Neurobiology of Aging 75 (2019) 136e149 143however, this failed to reach statistical signiﬁcance. When the data
from both tasks were converted to DRs, there was no signiﬁcant
difference between 2B3 and control IgG1kmice on the novelty test
(t < 1) but a signiﬁcant deﬁcit in 2B3 mice on the OiP task [t(13) ¼
2.66, p < 0.05; Supplementary Figure 1B]. Furthermore, both
groups performed the novel object recognition memory task
above chance (0.5), p’s < 0.01 (Supplementary Figure 1A). In
contrast, 2B3mice did not perform above chance level (0.5) on the OiP
task, p > 0.5, unlike WT IgG1k control mice, p < 0.01 (Supplementary
Figure 1B). These results indicate that 2B3 (but not a control IgG1k)
administered to normal WT mice leads to a selective disruption of
associative recognition memory.3.3. Experiment 3
Analysis of contact times with objects across sample trials for
both recognitionmemory tasks showed that all groups explored the
objects at similar levels, p > 0.05 (Supplementary Table 3B). All
mice also showed habituation of exploratory activity to objects, as
indicated by a decrease in contact times when comparing sample
trial 1 to sample trial 3, p’s < 0.001. Following contact time analysis
within the test phase of the object novelty and OiP tasks, mice
showed no signiﬁcant differences in overall contact times with all
objects p’s> 0.05 (Supplementary Table 4B). In the OiP task, despite
treatment groups showing numerical differences in contact times
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Figure 5. (continued).
C.E. Evans et al. / Neurobiology of Aging 75 (2019) 136e149144between objects in novel and familiar locations, all mice continued
to show a general preference to explore objects in novel locations
over familiar, p < 0.001. The same pattern was also observed in the
object novelty task.
However, analysis of the OiP test DRs revealed a signiﬁcant
time  treatment group interaction, F(2, 34) ¼ 3.41, p < 0.05.
Testing for simple main effects further revealed that, although
vehicle PDAPP mice showed a decline in OiP performance across
pre- and post-treatment time points, p < 0.01, IP administration of
2B3 prevented this decline, p > 0.05. Moreover, both WT and 2B3
PDAPP mice showed comparable performance (p > 0.05) and both
groups performed better than vehicle PDAPP mice, p values <0.001
(Fig. 4B). Analysis of the object novelty task DRs showed no effect of
treatment group, F(2, 34) ¼ 0.16, p > 0.1, or treatment group  time
interaction, F(2, 34) ¼ 0.27, p > 0.1, (Fig. 4C). To summarize, the
results showed that peripheral administration of 2B3 before the
onset of cognitive decline prevented the age-dependent deﬁcit in
associative recognition, without inﬂuencing object novelty detec-
tion, in PDAPP mice.
To establish the generality of the improvement in associative OiP
memory with 2B3, PDAPP mice were also tested on a spatial
working memory foraging task (Evans et al., 2018). Time to com-
plete the foraging task after vehicle or 2B3 administration was
similar between all groups, p > 0.05 (Supplementary Table 5),
which indicated that neither transgene expression nor 2B3
administration inﬂuenced the motivation to complete the task.However, foraging accuracy was improved in 2B3 PDAPP relative to
vehicle PDAPPmice (Fig. 4D and E). More speciﬁcally, analysis of the
mean total number of errors (a measure of overall foraging accu-
racy) revealed a signiﬁcant treatment time group interaction, F(2,
34) ¼ 3.68, p < 0.05. Tests of simple main effects showed that 2B3
PDAPP mice made less errors than their pre-drug assessment at
11 months of age, p < 0.05 and less errors than vehicle PDAPP mice,
p< 0.01 (Fig. 4D). In contrast, vehicle PDAPPmicemademore errors
than WT vehicle controls, p < 0.001 (Fig. 4D). WT mice and 2B3
PDAPP mice performed at a comparable level, p > 0.05. A similar
pattern of results was observed when analyzing repeat errors, a
measure of working memory (Fig. 4E). An ANOVA revealed a sig-
niﬁcant treatment time  group interaction, F(2, 34) ¼ 3.85, p <
0.05. Simple main effects analysis revealed that 2B3 PDAPP mice
made fewer repeat errors than vehicle PDAPP mice, p < 0.05, and
that there was no signiﬁcant change in the number of repeat errors
compared to pre-drug performance, p > 0.05. In contrast, vehicle
PDAPPmice showed an age-dependent increase in the total number
of repeat errors compared to pre-drug assessment, p< 0.05. Vehicle
PDAPP mice also made more repeat errors than WT mice, p < 0.01.
This impairment was not present in 2B3 PDAPP mice, p > 0.05.
3.4. Biochemical analyses: experiments 2a, 2b, and 3
In experiment 2a, Western blot analysis showed that ICV 2B3
administration caused no change in total levels of BACE1, F(2, 28) ¼
C.E. Evans et al. / Neurobiology of Aging 75 (2019) 136e149 1451.95, p > 0.1, or presenilin 1 (PS1), F(2, 28) ¼ 1.40, p > 0.1, in the
hippocampus of PDAPPmice (Fig. 5A). These datawere replicated in
the hippocampus of IP 2B3 mice for both BACE1, F(2, 25)¼ 2.30, p>
0.1, and PS1, F < 1 (Fig. 5B), and WT ICV 2B3 mice for BACE1, t(13)¼
0.5, p > 0.5 (Supplementary Figure 1D). Western blot analysis
showed an overall change in APP levels, F(2, 28) ¼ 8.49, p < 0.01 in
ICV 2B3 PDAPP mice (Fig. 5A). Post hoc Tukey tests revealed this
difference was evident only when comparing WT mice to PDAPP
vehicle, p < 0.01, and PDAPP 2B3 mice, p < 0.05. No difference in
APP levels was reported between the PDAPP groups, p > 0.1. ELISA
analysis further conﬁrmed that 2B3 caused no change in APP levels
in PDAPP mice after either ICV, t(18) ¼ 1.32, p > 0.1, or IP admin-
istration, t(17) ¼ 1.45, p > 0.1 (Fig. 5C and D, respectively). In
experiment 2b, there was similarly no change in endogenous APP
levels in WT mice administered 2B3, relative to IgG1k controls
t(13) ¼ 0.81, p > 0.5 (Supplementary Figure 1D).
In experiment 2a, ICV 2B3 administration caused a signiﬁcant
16% reduction in levels of bCTF, t(18) ¼ 2.22, p < 0.05, a signiﬁcant
56% reduction in levels of soluble Ab40, t(18)¼ 2.28, p< 0.05, and a
(nonsigniﬁcant) 66% reduction in levels of soluble Ab42, t(18) ¼
1.01, p > 0.1, in the hippocampus (Fig. 5E, F, and G, respectively; see
also in vitro data from Thomas et al., 2011b, 2013). In experiment
2b, there was a signiﬁcant 8.1% reduction in endogenous soluble
Ab40, t(13) ¼ 2.45, p < 0.05, in the hippocampus of WT ICV 2B3
mice relative to IgG1k control mice (Supplementary Figure 1E).
Endogenous soluble Ab42 was undetectable by ELISA and, there-
fore, could not be compared (data not shown). In experiment 3,
analysis of hippocampal tissue from IP 2B3 PDAPPmice revealed no
signiﬁcant change in soluble or insoluble Ab40 or Ab42 or bCTF
levels (data not shown) compared with vehicle PDAPP mice, t’s < 1
(Fig. 5H-K).
In experiment 2a, there were no signiﬁcant differences in the
total expression levels of the synaptic marker PSD95 or NMDA re-
ceptor subunits, NR1, or NR2B in hippocampal synaptosomes of ICV
[maximum NR2B, F(2, 28) ¼ 2.72, p > 0.05]. A similar pattern was
evident in experiment 3 after IP 2B3 administration (maximum
NR1, F(2, 26) ¼ 0.12, p > 0.1, respectively; Fig 6A, B and E). In
experiment 2a, phosphorylation of the NR2B Y1472 residue
appeared to be reduced in vehicle PDAPP mice, although this was
not signiﬁcant relative to WT mice or ICV 2B3 PDAPP mice, F(2,
28)¼ 2.36, p> 0.05 (Fig. 6A and B). However, after IP administration
of 2B3 (experiment 3), phosphorylation of the NR2B Y1472 residue
was signiﬁcantly altered in IP 2B3 PDAPP mice, F(2, 25) ¼ 3.86, p <
0.05, PDAPP vehicle mice showed reduced pY1472 compared with
WT vehicle mice, p < 0.05 (Fig. 6E). When NR2B Y1472 phosphor-
ylation was presented as a ratio of total NR2B, there was a signiﬁ-
cant difference between groups in both the ICV (experiment 2a),
F(2, 28) ¼ 16.11, p < 0.001 and IP (experiment 3) studies, F(2, 25) ¼
5.30, p < 0.01. Post hoc Tukey’s analyses revealed a reduction in
vehicle PDAPP mice compared with WT mice in both ICV and IP
groups (p < 0.001, p < 0.05; Fig. 6B and E). Furthermore, the ratios
were also reduced in vehicle PDAPP mice compared with 2B3
PDAPP mice, (p < 0.001, p < 0.05, respectively). Neither ICV nor IP
2B3 PDAPP mice differed relative to their respective WT control
mice, p values > 0.1.
Given the changes in NR2B phosphorylation, we investigated
SRC kinase Fyn and striatal-tyrosine-enriched phosphatase (STEP)
in hippocampal synaptosomes of ICV 2B3 PDAPP mice. These ki-
nases are key regulators of NR2B phosphorylation (Ittner et al.,
2010; Zhang et al., 2010). No change in total levels of Fyn be-
tween any of the groups was evident in hippocampal synapto-
somes, F< 1 (Fig. 6C). Conversely, both isoforms of STEP (46 and 61)
were numerically increased in vehicle PDAPP mice relative to WT
and 2B3 PDAPP mice (Fig. 6C). However, despite a numerical in-
crease in STEP61, there were no signiﬁcant differences betweengroups, F(2, 28) ¼ 2.48, p > 0.05. In contrast, STEP46 was altered
signiﬁcantly, F(2, 28) ¼ 4.39, p < 0.05. Post hoc Tukey’s analysis
revealed STEP46 was increased in vehicle PDAPP mice compared
with WT mice, p < 0.05 (there was a numerical difference between
PDAPP vehicle and 2B3 PDAPP mice, but it was not signiﬁcant; p ¼
0.074, 2B3; Fig. 6C).
Extracellular signaleregulated kinase (ERK) is downstream of
NMDA signaling and plays a role in regulating memory processes
(Caccamo et al., 2010). There was a signiﬁcant change in total ERK
levels [F(2, 28) ¼ 15.29, p < 0.001] in synaptosomes of ICV vehicle
PDAPP compared with WT (p < 0.01) and ICV 2B3 PDAPP mice (p <
0.001; Fig. 6D). There were no changes between ICV WT and 2B3
PDAPP mice in total levels of ERK, p> 0.1. Although phosphorylated
ERK appeared to be numerically reduced in ICV vehicle PDAPPmice,
there were no signiﬁcant differences between groups, F < 1. In
contrast, when pERK was expressed as a ratio of total ERK, to better
determine ERK activity, ICV vehicle PDAPP mice showed a signiﬁ-
cant difference, F(2, 28)¼ 7.03, p< 0.01, with a signiﬁcant reduction
compared with both WT (p < 0.05) and ICV 2B3 PDAPP mice
(p < 0.01). There was no signiﬁcant difference betweenWT and ICV
2B3 PDAPP mice, p > 0.05 (Fig. 6D).
3.5. Experiment 4
The aforementioned analyses suggested that the NR2B receptor
played an important role in associative recognition memory,
although there are relatively little published data to support this
conclusion. We therefore tested a separate group of 18-month-old
WT mice on the OiP task after the administration of the NR2B re-
ceptor antagonist, Ro25-6981. WT mice continued to show habit-
uation to objects across 3 sample phases after Ro25-6981 or vehicle
administration (Supplementary Table 6). Ro25-6981 did not change
overall object contact times of WT mice in either the sample or test
phases when compared with vehicle contact times, p’s > 0.05
(Supplementary Tables 6 and 7). Moreover, despite numerical dif-
ferences, both vehicle (p < 0.001) and Ro-25-6981 (p < 0.01) mice
explored objects in novel locations more than those in familiar lo-
cations (Supplementary Table 7). However, an analysis of the test
DR scores showed that Ro25-6981 impaired performance relative
to vehicle administration, t(9) ¼ 2.47, p < 0.05 (Fig. 6F). These data
conﬁrm that, under normal physiological conditions, the NR2B re-
ceptor plays a key role in associative recognition memory processes
in normal aged WT mice.
4. Discussion
Male PDAPP mice showed a selective age-dependent impair-
ment in associative recognition memory, while sparing object
novelty detection. Similar to previous studies, the age-dependent
decline in associative recognition memory coincided with a rise
in hippocampal Ab levels (Barker and Warburton, 2013; Good and
Hale, 2007; Hale and Good, 2005; Selkoe, 2001). ICV administra-
tion of the anti-APP antibody, 2B3, directed against the BACE1
cleavage site, reduced APP metabolism and lowered Ab and bCTF
levels in the hippocampus. The reduction in Ab was accompanied
by restoration of associative recognition memory in aged PDAPP
mice. Furthermore, longitudinal peripheral administration of 2B3
prevented the onset of associative recognitionmemory impairment
as well as a decline in spatial working memory in PDAPP mice at
15 months of age. A critically important aspect of our results is that
both ICV and IP administration of 2B3 normalized a deﬁcit in NMDA
receptor phosphorylation. Previous work in normal animals has
shown that hippocampal NMDA receptors are required for asso-
ciative recognition memory but not object novelty/familiarity dis-
criminations (Barker and Warburton, 2013). Our results are,
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Figure 6. Impaired NMDA-NR2B signaling causes OiP impairment, which is reversed by 2B3 in PDAPP mice. (A) Representative Western blots of hippocampal synaptosomes from
PDAPP mice administered 2B3 by ICV (n ¼ 10) or vehicle (n ¼ 11) andWT vehicle control (n ¼ 10). Blots demonstrate changes in NR2B phosphorylation and subsequent downstream
signaling cascades. No changes in total levels of PSD95, NR1 (total NMDA receptors) (relative toWTcontrol) were reported p > 0.05. (B) No signiﬁcant changes were reported in total
levels of NR2B or pY1472, p’s > 0.05. However, when pY1472 was expressed as a ratio of total NR2B, PDAPP vehicle mice showed a signiﬁcant reduction in NR2B phosphorylation
compared with WT (***p < 0.001) and 2B3 PDAPP mice (AAAp < 0.001). (C) No signiﬁcant changes were reported in total levels of the Src kinase Fyn, or STEP61 (p values > 0.05);
however, PDAPP vehicle mice showed a signiﬁcant increase in total levels of STEP46 compared with WT mice (*p < 0.05). (D) Total levels of ERK were increased in vehicle PDAPP
mice compared with WT (**p < 0.01) and 2B3 PDAPP mice (AAAp < 0.001). Despite an apparent numerical reduction in phosphorylated (active) ERK in vehicle PDAPP mice, no
signiﬁcant differences were reported (p values > 0.05). However, when phosphorylated ERK was expressed as a ratio of total ERK, vehicle PDAPP mice had a signiﬁcant reduction in
phosphorylated ERK compared with WT (*p < 0.05) and 2B3 PDAPP mice (AAp < 0.01). (E) A similar result was observed in PDAPP mice administered chronically with 2B3 by IP
injection. A representative blot demonstrates a reduction in NR2B pY1472. No signiﬁcant change was observed in total levels of NR2B (p values >0.1). Vehicle PDAPP mice showed a
signiﬁcant reduction in pY1472 compared with WT controls (*p < 0.05). When pY1472 was expressed as a ratio of total NR2B, vehicle PDAPP mice (n ¼ 10) showed a signiﬁcant
reduction in comparison to WT control (n ¼ 9; *p < 0.05) and 2B3 PDAPP mice (n ¼ 9;Ap < 0.05). There was no signiﬁcant difference when comparing WT and 2B3 mice. (F) DR
scores of the OiP task after Ro25-6981 administration, a selective NR2B antagonist, showed impaired OiP performance in 17- to 18-month-old WT mice (n ¼ 10) compared with
vehicle performance (**p < 0.01). All Western blot data were analyzed using 1-way ANOVA with Tukey post hoc analysis. DR scores were analyzed using paired-samples t-tests.
Error bars represent the SEM. Abbreviations: ANOVA, analysis of variance; DR, discrimination ratio; ERK, extracellular signaleregulated kinase; ICV, intracerebroventricular; IP,
intraperitoneal; OiP, object-in-place; SEM, standard error of the mean; WT, wild type.
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lation of Ab changes hippocampal synaptic events that underpins
memory (Guntupalli et al., 2016).
Previous work with PDAPP mice has reported an age-related
deﬁcit in object novelty detection (Dodart et al., 1999). However,
this result has not been replicated across laboratories (Chen et al.,
2000). This discrepancy may be related to the test procedure. Incontrast to our own study and that conducted by Chen et al., Dodart
et al. (1999) exposedmice to a single object in the sample phase and
presented a familiar and novel object in the test phase. This test
procedure confounded object novelty with object-location novelty.
Thus, the deﬁcit in PDAPP mice reported by Dodart et al. may have
reﬂected impaired processing of location information. Importantly,
with the exception of the present experiments, no study has
C.E. Evans et al. / Neurobiology of Aging 75 (2019) 136e149 147compared the impact of aging on object novelty and associative OiP
memory in the same PDAPP mice longitudinally, and our evidence
indicates an age-related sensitivity to associative object-location
memory or mismatch detection in PDAPP mice.
Before discussing the effects of 2B3 on APP processing and
cognition, it is worth highlighting 2 drawbacks of the study. One
drawback is that only male mice were tested. This strategy was
undertaken to minimize extraneous sources of variability in both
the behavioral and biological measures and thus maximize the
detection of cognitive and synaptic changes induced by 2B3.
Nevertheless, given the positive results of this study in male mice
and the fact that over 60% of patients with AD are female (“2015
Alzheimer’s disease facts and ﬁgures,” 2015), it would be important
clearly to test the assumption that aged female PDAPP mice would
also demonstrate cognitive and pathology beneﬁts from reducing
APP cleavage by BACE1.
A second drawback of the study is that the half-life of 2B3 has
yet to be established in vivo. Although a single weekly injection of
2B3 was sufﬁcient to alter NR2B expression and cognition in PDAPP
mice, there was no evidence of changes in brain amyloid levels,
unlike the ICV administration study. However, this lack of sensi-
tivity to any changes probably reﬂects the much lower levels of 2B3
reaching the brain after peripheral IP administration, (because of
the blood-brain barrier) compared with direct ICV administration.
Further research is required to assess the temporal dynamics of the
interactions of 2B3 with APP processing in vivo. Nevertheless, our
data present clear evidence that, even under a restricted set of
conditions, 2B3 has an impact on APP processing and memory.
Excess Ab production leads to changes in the dynamic properties
of hippocampal synaptic plasticity; promoting the induction of LTD
and impairing the induction of LTP (Hsieh et al., 2006). This change
in plasticity dynamics occurs through several mechanisms
involving NMDA receptors and intracellular calcium signaling.
Indeed, extra-synaptic NMDA-NR2B receptors have emerged as a
key factor in mediating the effects of amyloid on synaptic depres-
sion and toxicity (Kessels et al., 2013; Wang et al., 2013); for
example, low nanomolar levels of soluble Ab oligomers enhance
NR2B-mediated NMDA receptor currents and extra-synaptic re-
sponses (Li et al., 2011).
Excess Ab production can also result in activation of Fyn kinase,
which leads to phosphorylation of NR2B at Y1472 and stabilizes
expression of the receptor at themembrane surface. The effect of Ab
on Fyn kinase is counteracted by elevation of STEP (Ittner et al.,
2010; Zhang et al., 2010); for example, there is an age-related in-
crease in STEP levels in Tg2576 mice (Zhang et al., 2010). STEP, a
tyrosine phosphatase, dephosphorylates NR2B at the Y1472 site, as
well as Fyn kinase and AMPA receptors. STEP therefore controls
NMDA receptor activity by directly dephosphorylating NR2B and
deactivating Fyn kinase. The enhanced expression of NR2B seen
with Ab is thought to contribute ultimately to the loss of synaptic
connections (Boehm, 2013). In the present study, 2B3 (both ICV and
IP) reversed the phosphorylation of NMDA-NR2B pY1472 in hip-
pocampal synaptosomes, without affecting PSD95, NR1, or NR2B
expression. We further showed an increase in total levels of STEP in
vehicle PDAPP mice, which was numerically reduced after 2B3
administration. Activation of ERK, which is downstream of NMDA
receptor activity, plays a role in regulating memory processes
(Krapivinsky et al., 2003). Furthermore, dysregulation of NR2B/ERK
signaling has been reported in 3xTg mice in association with
elevated levels of amyloid (Caccamo et al., 2010). In the present
study, ERK activity was reduced when expressed as a ratio of total
ERK in hippocampal synaptosomes from PDAPP mice. The reduc-
tion in ERK was, however, reversed after 2B3 administration. Taken
together, this evidence suggests that the 2B3-mediated changes in
NR2B synaptic signaling processes contributed to the improvementin associative recognition memory in aged 2B3 PDAPP mice. In
support of this assertion, we showed for the ﬁrst time that selective
antagonism of NR2B receptors impaired associative OiP recognition
memory in WT mice.
It is important to acknowledge that other anti-APP-BACE1 and
immunization approaches have been investigated. Thus, Arbel et al.,
(2005) reported the activity of the antibody BBS1 also directed
against the BACE1 cleavage site of APP. In vivo administration of
BBS1 by osmotic minipumps to 3xTg mice for 28 days resulted in a
signiﬁcant improvement in object-novelty memory at 17-18 month
of age (Rabinovich-Nikitin et al., 2012). These improvements in
behavior were complemented by a signiﬁcant reduction in plaque
size, Ab load, and a 24% reduction in soluble Ab42 (Rabinovich-
Nikitin et al., 2012). Peripheral administration of BBS1 also resul-
ted in improved object-novelty memory and reduced inﬂammatory
markers in Tg2576 mice (Rakover et al., 2007) as well as reduced Ab
plaques and intracellular Ab load in mice with the hAPP V717L
Londonmutation (Arbel-Ornath et al., 2009). Despite the changes in
Ab production, BBS1 did not improve spatial reference memory, as
assessed in the water maze. Our current ﬁndings conﬁrm that steric
hindrance of APP processing by BACE1 can have beneﬁcial effects
on amyloid levels and associative spatial recognition memory
processes that rely upon the hippocampus. Unlike the present
study, however, the effect of BBS1 on synaptic processes sensitive to
amyloid accumulation was not examined. A related study by Chang
et al., (2007) immunized mice against memapsin-2 (BACE1) with
the hypothesis that anti-memapsin-2 antibodies would bind to
memapsin-2 located on the surface of neurons and, when endo-
cytosed, would interferewith the cleavage of APP and thus lower Ab
production. Immunization of Tg2576 with anti-M2 saw a reduction
in amyloid load and improvement in performance in a water maze
reference memory task. Unlike the present study, however, the
extent of the cognitive change was not indexed against WT control
mice but only vehicle-treated Tg2576 mice. However, taken
together, our results, and those of Chang (ibid), conﬁrm that
selectively targeting BACE cleavage of APP can have positive effects
on amyloid production and memory function. Importantly, how-
ever, our study is the ﬁrst to show that an anti-APP antibody tar-
geting the BACE1 cleavage site improved associative recognition
memory and spatial working memory and reduced phosphoryla-
tion of NMDA-NR2B receptors. In addition, it is worth noting that
2B3 caused a signiﬁcant reduction in levels of bCTF, an effect that
has not previously been reported with BBS1 or anti-M2. Increased
levels of bCTF have been observed in patients with AD, and recent
research has revealed an Ab-independent mechanism causing
dysregulation of endocytosis (Kim et al., 2015; Pimplikar et al.,
2010). Consistent with this evidence, genetic reduction in BACE1
activity in a mouse model of Down syndrome improved endosomal
volume and improved cholinergic markers without lowering Ab
levels (Jiang et al., 2016). It is possible, therefore, that the reduction
in bCTF levels by 2B3may have had a beneﬁcial impact on endocytic
pathways, and this possibility requires further investigation.
In terms of the clinical relevance of our ﬁndings, evidence is
beginning to emerge that some antibody-based therapies have a
positive impact on amyloid pathology and may be disease-
modifying in amyloid-positive patients (e.g., BAM2401, https://
www.eisai.com; aducanumab, Sevigny et al., 2016). Although
these ﬁndings are preliminary, the idea that such immunotherapies
may be useful in the context of treating individuals who are amy-
loid positive in old age is gaining traction. However, our evidence
that 2B3 disrupted associative (but not object novelty) recognition
memory in normal young mice conﬁrms that metabolism of APP by
BACE1 is an important physiological process that contributes to
memory in healthy controls (see also Blume et al., 2018; Ou-Yang
et al., 2018; and review by Zhu et al., 2018 for further discussion).
C.E. Evans et al. / Neurobiology of Aging 75 (2019) 136e149148Therefore, targeting this pathway in healthy presymptomatic aged
participants should be combined with close monitoring for dele-
terious changes in memory function.
As highlighted by Piton et al. (2018), modulation of BACE activity
remains a viable strategy in trials on prodromal and early AD. Our
data add to a growing body of preclinical evidence that selectively
modifying APP processing at an early stage of amyloid accumula-
tion in the aging amyloid-positive brain has a beneﬁcial effect on
cognition. It also conﬁrms that APP processing by BACE1 has a role
in normal memory function and that disruption to this equilibrium
is detrimental. An antibody therapy that targets APP processing by
BACE1 may therefore only have clinical relevance in the context of
amyloid-related cognitive changes in the elderly (see Farrell et al.,
2017; Hedden et al., 2012).
Conclusion
In conclusion, the present study has shown that selectively
inﬂuencing APP metabolism by reducing BACE1 activity by steric
hindrance with an antibody, reversed and protected against an age-
dependent associative recognition memory deﬁcit in PDAPP mice.
ICV administration of 2B3 reduced levels of soluble Ab and bCTF
without affecting total levels of APP, and both ICV and chronic IP
administration normalized the phosphorylation of NMDA-NR2B
receptors. These novel ﬁndings provide important evidence that
selective inhibition of APP processing at the BACE1 cleavage site can
improve both memory and markers of synaptic pathology in a
mouse model of age-related amyloid accumulation. Finally, the
results contribute to other ﬁndings suggesting that modiﬁcation of
APP processing, and associated downstream glutamatergic
signaling cascades, may be beneﬁcial in populations with altered
APP metabolism, including aged individuals (Rodrigue et al., 2012)
and those at high risk of AD.
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